🔗 Share this article

While the United States continues making sweeping changes to its vaccine schedules, one figure appears somewhat surprisingly: Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by casting doubt on coronavirus shots during the pandemic and has concentrated on possible fatalities after Covid vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Vaccine Program

Public health authorities planned to announce major changes to the pediatric vaccination calendar recently, synchronizing the US with Denmark’s immunization schedule, according to reports – a major change that would put the US out of alignment with many the international standard with little proof for improved outcomes. This reveal has been postponed until the next year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to address the audience at the gathering. She was just designated acting director of the FDA’s CDER, the fifth appointee to run the office this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the drug and biologics branches as Dr. Høeg and Prasad strengthen their influence at the FDA – and it points to a renewed priority upon dismantling long-standing vaccines at the FDA.

Høeg has frequently advocated for ending specific childhood vaccine recommendations in the US in order to be more similar to Denmark, a society with nationalized medicine and a number of inhabitants approximately the population of the state of Wisconsin.

To date public appearances, she has continued to focus on immunizations – traditionally the domain of Prasad, chief of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Expertise

The appointee has little discernible background in medication creation, approval processes or administrative roles, which has been standard for previous directors of the biologics center. She has served at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in leading a large organization. She is not an expert in industry regulation.”

Past commissioners of CBER would “be deeply familiar with legal statutes and the research of drug development”, noted Janet Woodcock. “Clearly, she lacks the kind of background that prior appointees who ran CBER have had.”

The drug center has an immense portfolio at the FDA, the former commissioner pointed out.

“Many people just focuses on the innovative therapies, but the off-patent medication office approves thousands of generic medications. There is also a biologic copycat branch, non-prescription drug unit and so forth, and each of these have to be managed,” she explained. “The responsibility you neglect, that is precisely what that I always told people is going to bite you.”

Furthermore, a significant leadership aspect to the position, which oversees more than 5,000 employees. “It is a massive administrative position, if you perform it correctly,” she concluded.

Official Statement and Contentious Policies

Regarding concerns about Dr. Høeg's qualifications and whether this selection indicates greater collaboration among agency officials on immunizations, a representative stated that the “inquiries are based on incorrect presumptions”.

“This background matches the responsibilities of her job,” the representative said, pointing to the period Dr. Høeg spent advising the agency head on “medication safety and approval science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg takes over the agency head's controversial priority voucher program, a disputed one-day therapy clearance system that apparently concerned her preceding directors. “By what process are these drugs being selected for this fast-track system? Who takes the calls?” Howard said. “There is a lot of confidentiality happening at the FDA right now.”

Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards less stringent regulations of most medications, except for immunizations.”

Public Track Record on Vaccines

With immunizations, Dr. Høeg has a more documented, if problematic, history, critics observe. She authored a study using unconfirmed volunteer-provided data to estimate the frequency of heart inflammation after Covid vaccination. She advised the state of Florida top health official Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are pose a greater threat than they are.

Among her “wish list” for the new federal leadership included altering regulations for new vaccines and ending “non-essential” vaccines, she remarked post-election on a podcast. At the agency, Høeg has according to sources floated the idea of excluding teenage boys from obtaining COVID-19 vaccinations.

“She is an complete true believer who commences with her beliefs and reverse-engineers to fit the evidence in a very deceptive, fraudulent manner,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg became part of fellow contrarians, {like|